EMERYVILLE, Calif. & DENVER--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) and ArrowMark Partners ("ArrowMark†) today announced the signing of a license and services agreement for novel OmniAb-derived antibody discovery programs with Mabtrx Biosciences, a wholly owned subsidiary of AMVKG LS, a joint venture (JV) between ArrowMark and Viking Global Investors ("Viking†). Under the terms of the license and services agreement, OmniAb will receive revenue for services performed as well as potential equity and ...